Skip to main content

Table 2 Correlation of 21-gene Recurrence score (RS) including different cut-off values with Ki 67 scores and histopathological factors

From: Favorable locoregional control in clinically node-negative hormone-receptor positive breast cancer with low 21-gene recurrence scores: a single-institution study with 10-year follow-up

Characteristics

RS ≥ 11 (n = 50)

p-value

RS ≥ 18 (n = 25)

p-value

RS ≥ 26 (n = 7)

p-value

RS ≥ 31 (n = 4)

p-value

pT1(n = 49) vs. pT2 (n = 12)

41/49 (83.7%) vs. 9/12 (75%)

0.676

20/49 (40.8%) vs. 5/12 (41.7%)

0.999

5/49 (10.2%) vs 2/12 (16.7%)

0.615

4/49 (8.2%) vs. 0/12 (0%)

0.576

HG low & intermediate (n = 51) vs. high HG (n = 10)

40/51(78.4%) vs. 10/10 (100%)

0.184

16/51(31%) vs. 9/10 (90%)

0.001

3/53 (5.7%) vs. 2/8 (25%)

0.080

2/51 (3.9%) vs. 2/10 (20%)

0.122

NG low & intermediate (n = 45) vs high NG (n = 16)

35/45 (77.8%) vs. 15/16 (93.75%)

0.259

15/45 (33.3%) vs. 10/16 (62.5%)

0.074

1/45 (2.2%) vs. 6/16 (37.5%)

0.001

1/45 (2.2%)vs 3/16 (18.75%)

0.05

LVI (-) (n = 49) vs. LVI( +) (n = 10)

39/49 (79.6%) vs. 9/10 (90%)

0.670

17/49 (34.7%) vs. 6/10 (60%)

0.166

5/49 (10.2%) vs. 1/10 (10%)

0.999

3/49 (6.1%)vs 1/10 (10%)

0.534

Ki-67 < 15% (n = 29) vs. ≥ 15% (n = 32)

22/29 (75.9%) vs. 28/32 (87.5%)

0.323

10/29 (34.5%) vs. 15/32 (46.9%)

0.435

1/29 (3.4%) vs. 6/32 (18.75%)

0.106

1/29 (3.4%) vs. 3/32 (9.4%)

0.615

Ki-67 < 20% (n = 42) vs. ≥ 20% (n = 19)

33/42 (78.6%) vs. 17/19 (89.5%)

0.476

14/42 (33.3%) vs. 11/19 (57.9%)

0.094

3/42 (7.1%) vs. 4/19 (21%)

0.190

2/42 (4.8%) vs. 2/19 (10.5%)

0.582

Ki-67 < 25% (n = 50) vs. ≥ 25% (n = 11)

40/50 (80%) vs. 10/11 (90.9%)

0.670

17/50 (34%) vs. 8/11 (72.7%)

0.038

3/50 (6%) vs. 4/11 (36.4%)

0.016

2/50 (4%) vs. 2/11 (18.2%)

0.146

Ki-67 < 30% (n = 53) vs. ≥ 30% (n = 8)

42/53 (79.2%) vs. 8/8 (100)

0.330

18/53 (34%) vs. 7/8 (87.5%)

0.006

3/53 (5.7%) vs. 4/8 (50%)

0.004

2/53 (3.8%) vs. 2/8 (25%)

0.08

  1. RS Recurrence score